Montag & Caldwell LLC Sells 9,332 Shares of Edwards Lifesciences Co. (NYSE:EW)

Montag & Caldwell LLC trimmed its position in Edwards Lifesciences Co. (NYSE:EW - Free Report) by 9.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 91,859 shares of the medical research company's stock after selling 9,332 shares during the quarter. Edwards Lifesciences makes up approximately 1.5% of Montag & Caldwell LLC's portfolio, making the stock its 28th biggest holding. Montag & Caldwell LLC's holdings in Edwards Lifesciences were worth $6,800,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of EW. Crowley Wealth Management Inc. bought a new position in shares of Edwards Lifesciences in the 4th quarter worth $26,000. Millstone Evans Group LLC purchased a new stake in Edwards Lifesciences during the fourth quarter valued at about $29,000. Migdal Insurance & Financial Holdings Ltd. bought a new stake in Edwards Lifesciences during the fourth quarter worth about $30,000. Roble Belko & Company Inc purchased a new position in shares of Edwards Lifesciences in the 4th quarter worth about $46,000. Finally, Catalyst Capital Advisors LLC bought a new position in shares of Edwards Lifesciences during the 4th quarter valued at about $54,000. 79.46% of the stock is currently owned by institutional investors.

Edwards Lifesciences Stock Up 0.5 %

EW stock traded up $0.36 during midday trading on Friday, hitting $71.56. The stock had a trading volume of 3,235,636 shares, compared to its average volume of 4,927,071. The business has a 50-day moving average of $71.31 and a two-hundred day moving average of $70.85. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89. The firm has a market cap of $42.07 billion, a price-to-earnings ratio of 10.27, a price-to-earnings-growth ratio of 4.82 and a beta of 1.15. Edwards Lifesciences Co. has a 52-week low of $58.93 and a 52-week high of $95.25.

Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its quarterly earnings results on Tuesday, February 11th. The medical research company reported $0.59 EPS for the quarter, topping analysts' consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. As a group, equities research analysts forecast that Edwards Lifesciences Co. will post 2.45 earnings per share for the current fiscal year.

Analysts Set New Price Targets

EW has been the topic of several recent research reports. Evercore ISI reduced their target price on shares of Edwards Lifesciences from $75.00 to $73.00 and set an "in-line" rating on the stock in a report on Wednesday, February 12th. Truist Financial decreased their price objective on Edwards Lifesciences from $78.00 to $75.00 and set a "hold" rating on the stock in a report on Friday, April 11th. Wolfe Research lowered Edwards Lifesciences from a "hold" rating to a "strong sell" rating in a research note on Wednesday, February 12th. Canaccord Genuity Group raised their price target on Edwards Lifesciences from $68.00 to $71.00 and gave the stock a "hold" rating in a research report on Thursday, February 13th. Finally, Royal Bank of Canada reiterated an "outperform" rating and issued a $85.00 price objective on shares of Edwards Lifesciences in a research report on Wednesday, February 12th. One equities research analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and ten have issued a buy rating to the company. Based on data from MarketBeat, Edwards Lifesciences presently has a consensus rating of "Hold" and an average target price of $78.55.

Insider Activity

In related news, VP Donald E. Bobo, Jr. sold 6,500 shares of the company's stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $75.75, for a total transaction of $492,375.00. Following the completion of the sale, the vice president now owns 46,936 shares in the company, valued at approximately $3,555,402. This represents a 12.16 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Steven R. Loranger sold 5,739 shares of the stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $76.42, for a total transaction of $438,574.38. Following the completion of the transaction, the director now owns 60,372 shares in the company, valued at $4,613,628.24. This trade represents a 8.68 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 71,853 shares of company stock valued at $5,163,062 over the last ninety days. 1.29% of the stock is currently owned by corporate insiders.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.